These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1061 related items for PubMed ID: 20685256

  • 21. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
    Kim H, Lee KH, Kim I, Sohn SK, Jung CW, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Kim MK, Bae SH, Shin HJ, Won JH, Lee WS, Oh S, Kim HJ, Park JH, Korean Society of Blood and Marrow Transplantation.
    Leuk Res; 2014 Jul; 38(7):730-6. PubMed ID: 24840870
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Kodera Y, Miyamura K.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Novitzky N, Thomas V, du Toit C.
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):584-8. PubMed ID: 23270985
    [Abstract] [Full Text] [Related]

  • 27. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Al-Zahrani H, Nassar A, Al-Mohareb F, Al-Sharif F, Mohamed S, Al-Anazi K, Patel M, Rasheed W, Saleh AJ, Bakr M, Ahmed S, Ibrahim K, Hussain F, Elkum N, Elhassan T, Nurgat Z, Chaudhri N, Aljurf M.
    Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
    [Abstract] [Full Text] [Related]

  • 28. Successful Outcome With Fludarabine-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation From Related Donor in Fanconi Anemia: A Single Center Experience From Turkey.
    Kuşkonmaz B, Ünal Ş, Bayhan T, Aytaç Eyüboğlu S, Tavil B, Çetin M, Gümrük F, Uçkan Çetinkaya D.
    Pediatr Blood Cancer; 2016 Apr; 63(4):695-700. PubMed ID: 26703084
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Raida L, Tucek P, Faber E, Vondrakova J, Rusinakova Z, Skoumalova I, Hubacek J, Jarosova M, Katrincsakova B, Pikalova Z, Kurfurst P, Indrak K.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
    [Abstract] [Full Text] [Related]

  • 31. Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
    Takpradit C, Prockop SE, Kernan NA, Scaradavou A, Curran K, Ruggiero J, Zakak N, O'Reilly RJ, Boulad F.
    J Pediatr Hematol Oncol; 2018 May; 40(4):e220-e224. PubMed ID: 29432302
    [Abstract] [Full Text] [Related]

  • 32. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M, Or R, Shapira MY, Aker M, Resnick IB, Ackerstein A, Samuel S, Elad S, Slavin S.
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
    Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J, Giller RH, Shimamura A, Delaney C, Skoda-Smith S, Thakar MS, Baker KS, Rawlings DJ, Englund JA, Flowers ME, Deeg HJ, Storb R, Woolfrey AE.
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1996-2003. PubMed ID: 25196857
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE.
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [Abstract] [Full Text] [Related]

  • 39. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Modi D, Singh V, Kim S, Ayash L, Deol A, Ratanatharathorn V, Uberti JP.
    Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
    [Abstract] [Full Text] [Related]

  • 40. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
    Srinivasan R, Takahashi Y, McCoy JP, Espinoza-Delgado I, Dorrance C, Igarashi T, Lundqvist A, Barrett AJ, Young NS, Geller N, Childs RW.
    Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.